Abstract Medulloblastoma is one of the leading causes of morbidity and mortality in pediatric cancer. Wnt-active tumors, an independent molecular subgroup in medulloblastoma, are characterized by a distinct pattern of genomic aberrations. We assessed the anticancer activity of cantharidin and norcantharidin against medulloblastoma, as cell lines in vitro and in athymic nude mice in vivo. Cantharidin and norcantharidin treatment impaired the growth of DAOY and UW228 medulloblastoma cells and promoted the loss of b-catenin activation and the b-catenin nuclearization linked to N-cadherin impairment in vitro. Intra-peritoneal administration of norcantharidin inhibited the growth of intra-cerebellum tumors in orthotopic xenograft nude mice. Analysis of the xenograft tissues revealed enhanced neuronal differentiation and reduced b-catenin expression. Our findings suggest that norcantharidin has potential therapeutic applications in the treatment of medulloblastoma as a result of its ability to cross the blood-brain barrier and its impairment of Wnt-b-catenin signaling.
Introduction
Medulloblastoma (MB) is a highly invasive embryonal neuroepithelial tumor of the cerebellum. It is the most common malignant brain tumor in children, and occurs bimodally, with peaks of incidence between 3-4 years and between 8-9 years of age, although it is also found in adults, with the highest incidence at 20-34 years of age [1] .
MB formation and growth have been associated with multiple molecular dysfunctions. These include deregulation of molecular pathways known to have important roles in cerebellum development, for example sonic hedgehog (Hh), notch, and wingless (Wnt) signaling [2] [3] [4] [5] .
Over the past three decades, multiple markers have been developed that hold promise for better prognostic stratification and more individualized therapy for pediatric MB [6] [7] [8] [9] . Recent gene-expression profiling studies have suggested four molecular subtypes of MB, each of which is characterized by a distinct genetic profile, distinct activation of oncogenic pathways, and varied clinical outcomes. Thus, within MB, subgroup A is characterized by Wnt signaling, subgroup B by Hh signaling, and subgroups C and D by expression of neuronal differentiation and photoreceptor genes [10, 11] . Literature data further indicate that although Wnt tumors are classic MB, and most Hh tumors are desmoplastic MB, the Wnt and Hh subgroups always cluster together, suggesting they are biologically similar [11] . Moreover a number of gene targets of the Wnt pathway are found to be up-regulated in desmoplastic relative to classic MB cell lines, consistent with aberrant activation of Wnt pathway in desmoplastic MB, thus definitely implying a Wnt-driven role in these tumors [12, 13] .
The treatment currently used for management of MB includes tumor resection, radiotherapy, and chemotherapy; however, at present, 15% of patients die of treatmentrelated toxicity [14] . For younger patients, chemotherapy is widely used as the initial treatment, with the objective of also delaying or avoiding radiation therapy, which can often result in severely deleterious effects on the craniospinal axis. Furthermore, MB survivors commonly develop serious late morbidities that are associated with late treatment effects [4, 8] .
In addition to characterizing an independent subgroup of genomic aberrations, Wnt-activated tumors occur in 10% to 15% of MBs and Wnt has recently been described as a marker of favorable patient outcome [10, [15] [16] [17] . Because of this wide involvement of Wnt signaling in MB, compounds targeting Wnt signaling will not only make treatment more effective, but also enable reduction of neurotoxic therapy.
Activation of the Wnt pathway inhibits glycogen synthase kinase (GSK)-3b-dependent phosphorylation of b-catenin. Stabilized, hypo-phosphorylated b-catenin translocates to the nucleus and interacts with transcription factors of the T-cell factor/lymphoid enhancer factor-1 (TCF/LEF-1) family, leading to an increase in the expression of genes such as c-MYC, which ultimately establishes the oncogenic phenotype [18] .
In this study, we show cantharidin (CTD) and norcantharidin (NCTD) suppression of Wnt-b-catenin signaling in MB cell lines. CTD is a natural compound that was originally isolated from beetles and that has traditionally been used as an anticancer agent [19, 20] . Clinical use of CTD has, however, been limited, because of its severe side effects, with analogs of CTD synthesized in attempts to reduce its highly toxic nature [21, 22] . In recent studies, CTD and its derivatives have been shown to have strong in vitro antitumor activity in cells representative of a variety of cancers, for example leukemia [23] , colorectal carcinoma, hepatoma, bladder carcinoma, myeloma, and breast cancer [19, 22, [24] [25] [26] . NCTD is a demethylated CTD analog [25] [26] [27] . In addition to inhibition of the proliferation of a range of cancer-specific cells, NCTD potently inhibits angiogenesis and breast cancer cell-line metastases, without significant renal or liver toxicity [28] [29] [30] [31] [32] [33] [34] .
CTD and NCTD are known to inhibit protein phosphatases 1 and 2A (PP1, PP2A), both of which are involved in the regulation of multiple cellular processes, including signal transduction pathways, cell-cycle progression, glucose metabolism, and calcium transport [35] [36] [37] [38] . PP2A has a positive role in Wnt signaling through its regulation of b-catenin stability [36] . Here, we report results that indicate that CTD and NCTD block Wnt-b-catenin signaling in vitro, with impaired nuclear translocation of b-catenin. NCTD can also reduce the sizes of intracranial tumors in a mouse orthotopic xenograft model in vivo, with enhanced neuronal differentiation. Our results establish a role for NCTD in the treatment of brain cancers, because it can cross the blood-brain barrier (BBB). This thus enhances the potential for future use of NCTD to treat patients suffering from MB.
Materials and methods

Cell lines, antibodies, and reagents
The human embryonic kidney (HEK)293T cell line and the human classic ONS76 and UW228 MB cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The human desmoplastic DAOY MB cell line was cultured in Eagle's minimum essential medium supplemented with 10% fetal bovine serum. CTD and NCTD were purchased from Sigma Chemical (St Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO). Fresh aliquots diluted in phosphate-buffered saline (PBS) were used for in-vitro experiments. The antibodies used were: anti-b-catenin and anti-N-cadherin (BD Biosystems, San Diego, CA, USA), anti-activated-b-catenin (Millipore, Billerica, MA, USA), anti-b-actin (Sigma), anti-survivin and anti-XIAP (Cell Signaling, Danvers, MA, USA), and horse-radish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies (GE Healthcare Life Sciences, Milan, Italy).
Cell viability assay
The MB cell lines were seeded into 96-well plates at a density of 10 4 cells per well. After treatment for 72 h with CTD and NCTD at different concentrations, the metabolic activity of the treated samples was assessed as a surrogate marker for cell proliferation, using the 3-(4,5-dimethylthiazol-2-yl)-5-diphenyltetrazolium bromide (MTT; Sigma) assay, as previously described [39] . Each result is the mean ± standard deviation (SD) from six replicates, and each experiment was repeated at least three times.
Apoptosis assay
Caspase activity was measured in accordance with the manufacturer's procedure (BD Biosciences). Briefly, cell lysates (100 lg total protein) were added to reaction mixtures (final volume, 100 ll) containing fluorigenic substrate peptides specific for caspase 3 (DEVD-AFC). The reactions were performed at 37°C for 1 h. Fluorescence was measured with a fluorescence microplate reader (excitation wavelength 400 nm; EnVision 2102 Multilabel Reader; Perkin Elmer, Waltham, MA, USA). Each result is the mean ± standard deviation (SD) from six replicates.
Flow cytometric analysis for cell-cycle distribution After CTD (5 lM) or NCTD (40 lM) treatment, the cells were harvested by brief trypsinization, then washed twice with ice-cold PBS. The cell pellets were collected, and approximately 0.5 9 10 5 cells were resuspended in 20 lg/ ml propidium iodide solution, and incubated at 4°C for 24 h in the dark. The cell-cycle distribution was then analyzed by flow cytometry using fluorescence-activated cell sorting analysis (BD FACS, Canto II; BD Biosciences).
Luciferase reporter assay HEK293T cells were seeded into 96-well plates at a density of 10 5 cells/well, and grown for 12 h. The cells were transfected using CaCl 2 and HEPES-buffered saline solution with 15 ng Renilla luciferase plasmid, 65 ng pCAN-bcatenin or pCAN plasmid, and 25 ng pGl3 plasmid or one of the two firefly luciferase reporter structures-TOP-FLASH, containing four Tcf consensus binding sites upstream of the firefly luciferase cDNA, or FOP-FLASH, a plasmid with mutated Tcf binding sites (a gift from Thomas Clevers; Upstate Biotechnology, Waltham, USA). After overnight incubation, the cells were further incubated with CTD and NCTD dissolved in DMSO, at 37°C for 24 h. After this incubation, the total cell lysates were extracted with Passive Lysis Buffer (Promega, Madison, USA; Code E194A), and the luciferase activity was determined by means of the Dual-Luciferase Assay (Promega), using a microplate luminometer (EnVision 2102 Multilabel Reader; Perkin Elmer, Waltham, MA, USA). TOP-structure luciferase activity was normalized relative to luciferase activity in the Renilla luciferase plasmid and is reported as relative luciferase units (RLU). The FOPstructure was used as negative control for TOP-structure luciferase activity. Each result is the mean ± standard deviation (SD) from six replicates, and each experiment was repeated at least three times.
Western blotting
Extraction of proteins from cultured cells was followed by immunoblotting with the relevant antibodies, as described elsewhere [39] . Each experiment was repeated at least three times.
Immunoflourescence assay
Immunofluorescence staining was conducted with DAOY and UW228 cells cultured on cover slips. The cells were fixed in 4% paraformaldehyde and permeabilized for 10 min in buffer containing 0.1% Triton X-100. The relevant antibodies were then added at the dilutions recommended by the manufacturers. Laser-scanning confocal microscopy was carried out using an MRC-1024/ES confocal microscope (Bio-Rad, Hercules, USA).
Reverse-transcription polymerase chain reaction (RT-PCR) and quantitative PCR Total RNA was extracted using Trizol reagent (Invitrogen, Milan, Italy). Reverse transcription was as a random hexamer and superscript II reverse transcription (Invitrogen). PCR was carried out with the following 5 0 -3 0 primers: TUBB3 forward: TGCGTGAGGAGTATCCCGAC, reverse: CGTGTCTGACACCTTGGGTG; GFAP forward: GGAAG CTGCTAGAGGGCGA, reverse: TCGAATCTGCAGGTTG GAGAA; MAP2 forward: ATCATGGACGCTGACAGCCT, reverse: TCTAACTGTTCTGTCATGATGCTCC; Gabra6 forward: TCCGTCCCAGCAAGAACTGT, reverse: CGGGC ACTGATGCTCAAAGT; GAPDH forward: GAAGGTGA AGGTCGGAGTC, reverse: GAAGATGGTGATGGGATT TC. Quantitative syber green PCR kits (Qiagen, Milan, Italy) were used for quantitative PCR. For all of the syber Green PCR, C t values were normalized to GAPDH. All real-time quantitative reverse-transcription PCR results are reported as the mean ± SD from two or three replicate experiments.
In vivo experiments
Sixteen SCID nude mice (6-8 weeks old; Harlan Laboratories, Udine, Italy) were injected intracerebellary with 2 9 10 5 DAOY cells that stably over-expressed the luciferase gene, to establish cerebellar tumors. Tumor cell growth was monitored weekly by measuring the luminescence emission referred to as the bioluminescence imaging (BLI) levels (photon/s/cm 2 ), by use of an IVIS 3D Illumina imaging system (Xenogen Corp. Alameda, USA), as previously described [40] . Three weeks after implantation, the mice were divided into two homogeneous groups based on their BLI levels. The first group (eight mice) was treated with NCTD (1 mg/kg/day), the other group (eight mice) with the DMSO vehicle, for 10 consecutive days, by intraperitoneal injection.
Statistical analysis
The unpaired Student's t-test was used to evaluate the statistical significance of in-vitro and in-vivo treatments. Statistical significance was established at *P B 0.5 9 10 -2 , **P B 0.5 9 10 -4 , ***P B 0.5 9 10 -6 .
Results
CTD and NCTD suppressed growth of MB cell lines
The effects of CTD and NCTD on the viability of the MB cell lines were assessed by use of the MTT metabolic assay after treatment for 72 h. The two compounds were dissolved in PBS, to limit DMSO toxicity to the cells. CTD at concentrations higher than 30 lM rapidly inhibited cell proliferation, with the cells killed in \24 h (data not shown). In contrast, treatment with CTD at lower concentrations (1, 5, 10, 20, and 30 lM) was not as toxic at 24 h. For the DAOY cells and treatment for 72 h, for CTD the IC 50 for cell viability was 5.0 ± 0.4 lM (*P = 0.5 9 10 -2 ). The UW228 cells were more resistant to the toxic effects of CTD, and for CTD the IC 50 for cell viability was 20 ± 2.0 lM (**P = 0.2 9 10 -4 ) (Fig. 1a) . NCTD was not as toxic to these cells, and 10 and 20 lM NCTD had no apparent effects on cell viability. For the DAOY cells, for NCTD the IC 50 for cell viability was 40 ± 2.9 lM (*P = 4.5 9 10 -3 ) and for UW228 cells it was 52 ± 5.0 lM (*P = 0.3 9 10 -2 ) (Fig. 1b) . With the ONS76 MB cell line, after treatment for 72 h, for CTD the IC 50 for cell viability was 4.2 ± 1.0 lM (*P = 0.3910 -2 ). NCTD was not toxic to these cells (Online Resource 1).
We observed that after treatment with CTD or NCTD for 24 h, DAOY and UW228 cells became detached from the plastic plates. Cell rounding and detachment were visualized by phase-contrast microscopy (Fig. 1c) . To investigate the effects of CTD and NCTD further, the specific treatments of the DAOY and UW228 cells with 5 lM CTD or 40 lM NCTD were maintained for 24 h, conditions under which 50% of the cells became detached from the plastic plates.
At these compound concentrations, N-cadherin protein level decreased in MB cell lines (DAOY, UW228, ONS76), as shown using Western blotting (Fig. 1d) , (Online Resource 1), an effect apparent from the loss of the ability of these cells to remain attached to the plates.
CTD and NCTD increased caspase-3 activity and cell cycle arrest at the G2 phase in MB cell lines
The apoptotic effects of CTD and NCTD by anoikis was quantified by activation of caspase-3 (Fig. 1e) . For DAOY cells, treatment with 5 lM CTD induced 8.4-fold activation of caspase-3 (***P = 6.2 9 10 -10 ); for UW228 cells, 3.2-fold activation was induced (***P = 3.5 9 10
-6
). For DAOY cells, treatment with 40 lM NCTD induced 8.0-fold activation of caspase-3 (***P = 1.9 9 10 -6 ); for UW228 cells, 2.3-fold activation was induced (**P = 2.0 9 10 -5 ). For control HEK293T cells activation of caspase-3 was not observed, which suggests that CTD and NCTD induce selective cytotoxicity in these MB cell lines. Caspase-3 activation for CTD or NCTD-treated cells was represented as a multiple of caspase-3 activation for PBS-treated cells.
To further characterize the growth arrest, these MB cell lines were treated with 5 lM CTD or 40 lM NCTD, and after 24 h they were subjected to FACS analysis of propidium-iodide-stained cells. These analyses indicated that the number of cells in the G2 phase had increased. Treatment with NCTD resulted in accumulation of cells in the G2 phase, with approximately 32% DAOY cells and 55% UW228 cells in the G2 phase compared with 14% DAOY and 14% UW228 for PBS-treated cells. CTD had minor effects, with 25% DAOY and 25% UW228 cells in the G2 phase compared with 14% DAOY and 14% UW228 for PBS-treated cells (Fig. 1f) . For ONS76 cells also, CTD and NCTD treatment resulted in accumulation of cells in the G2 phase compared with PBS-treated cells (Online Resource 1).
CTD and NCTD impairment of Wnt/b-catenin signaling assessed by TOP/FOP luciferase assays Because CTD and NCTD are known to impair PP2A, which in turn affects b-catenin phosphorylation [36] , we investigated whether these compounds were able to impair Wnt-b-catenin signaling. The HEK293T cells were used as the model cell system, and were co-transfected with three different plasmids for each experimental point: the TOPstructure or FOP-structure or pGl3 plasmid, the pCAN-bcatenin or pCAN plasmid, and the Renilla luciferase plasmid. As shown in Fig. 2a , for HEK293T cells treated with 5 lM CTD the luciferase activity established by TOPstructure and pCAN-b-catenin plasmid was significantly reduced, by 80%, compared with the luciferase activity established in DMSO-treated control cells (***P = 1.3 9 10 -11 ). Also, 40 lM NCTD was sufficient to impair approximately 50% of the luciferase activity established by TOP-structure and pCAN-b-catenin plasmid (***P = 5.8 9 10 -9 ), with compared with DMSO-treated control cells (Fig. 2b) . We did not observe any reductions in the viability of transfected and treated HEK293T cells (data not shown).
CTD and NCTD impairment of Wnt/b-catenin signaling through nuclear b-catenin loss Literature data describe b-catenin and Wnt-target proteins and their expression in DAOY, UW228, and ONS-76 cell lines; those proteins are highly correlated with similar expression level in MB specimens [41] . Western blotting of total protein extracts from DAOY and UW228 cells revealed reduced total b-catenin content after 40 lM NCTD treatment. In 5 lM CTD-treated cells, no such strong effect was observed. The amount of activated b-catenin available to drive Wnt-target transcription in the nucleus was revealed using an anti-activated-b-catenin antibody that is specific for the active form of b-catenin, which is dephosphorylated on its Ser37 and Thr41 amino-acid residues [42] . This was strongly reduced after CTD and NCTD treatment. Levels of the protein survivin, a known Wnt target, were also significantly reduced (Fig. 2c) . These effects were also observed in ONS76 cells although 40 lM NCTD did not strongly reduce activated-b-catenin expression (Online Resource 2). The inhibitor of apoptosis XIAP is expressed after apoptotic extrinsic signals that are independent of the Wnt signaling pathway. Its levels were not affected in these treated MB cell lines, except in the UW228 cells treated with 40 lM NCTD. In contrast, in ONS76 cells we observed increased XIAP expression (Online Resource 2). These results demonstrated the specific function of both CTD and NCTD against activation of the Wnt-b-catenin signaling pathway.
Immunofluorescence assays in the DAOY and UW228 MB cell lines treated with PBS revealed nuclear location of b-catenin. After the CTD and NCTD treatment, b-catenin was mainly located under the plasma membrane (Fig. 2d) . In PBS-treated cells, perinuclear location was observed for E-cadherin, with some punctate staining in the endoplasmic reticulum; after CTD and NCTD treatment, a pattern of staining under the plasma membrane was observed for E-cadherin, where it was co-located with b-catenin (Fig. 2d) .
NCTD treatment enhances neuronal marker gene expression
Impairment of cell proliferation might affect cellular differentiation. To investigate this hypothesis, we evaluated expression of the neuronal marker genes GFAP, GABRA6, MAP-2, MATH3, and TUJ1 in these MB cell lines after treatment with CTD and NCTD. The levels of mRNA expression from these genes were represented as multiples of 2
-DCT values compared with PBS-treated cells. GFAP, MAP-2, and TUJ1 gene expression levels were not significantly affected by these treatments (Fig. 3a, b) . After treatment of DAOY cells with 5 lM CTD for 24 h there were increases in mRNA expression for GABRA6 (3.5-fold ± 0.3-fold; ***P = 1.0 9 0 -8 ) or MATH3 (2.4-fold ± 0.15-fold; ***P = 5.0 9 10 -8 ), which are two cerebellar granule cell markers. After treatment of DAOY cells with 40 lM NCTD for 24 h, there were increases in mRNA expression for GABRA6 (7.5-fold ± 0.7-fold; ***P = 3.4 9 10 -7 ) and MATH3 (4.3-fold ± 0.2-fold; ***P = 2.6 9 10 -9 ) (Fig. 3a ). There were also increases in mRNA expression for UW228 cells (GABRA6, 5.8-fold ± 0.7-fold; ***P = 6.3 9 0 -10 ; and MATH3, 4.9-fold ± 0.2-fold; ***P = 3.7 9 10 -8 ) (Fig. 3b ) and ONS76 cells (GABRA6, 4.2-fold ± 0.7-fold; *P = 0.1 9 10 -2 ; and MATH3, 2.8-fold ± 0.8-fold; *P = 0.4 9 10 -2 ) (Online Resource 3). These results emphasize the enhancement of cell differentiation processes in these MB cell lines after NCTD treatment.
NCTD treatment impairs the growth of intra-cerebellum DAOY-luc implanted cells in a xenograft animal model
In clinical trials, CTD has been shown to be severely toxic to mucous membranes, mainly in the gastrointestinal tract, urethra, and kidney, with the dose-limiting factor of renal toxicity; in contrast, such toxicity is not observed for NCTD treatment [21, 22, 33, 43] . These findings prompted us to investigate the efficacy of NCTD to impair MB tumor growth in vivo, using MB orthotopic xenograft animal models. Previously generated bioluminescent DAOY cells stably overexpressing luciferase protein were evaluated for their signaling activation pathways as reported by Garzia et al. [40] . DAOY-luc cells were implanted into the cerebellum of 16 young NOD/SCID mice (six weeks of age). The mice were divided into two groups and were treated for ten consecutive days with vehicle (DMSO) or with NCTD (1 mg/kg/day). Tumorigenesis was evaluated using in vivo bioluminescence assays and BLI levels were taken at implantation (T0) and 5 (T1) and 10 (T2) days afterwards (Fig. 4a) . The BLI mean values for each mouse are shown in Table 1 . The T1 values were the highest BLI values for the NCTD-treated mice. As shown in Fig. 4b , photons/s recorded at different times of treatment (T0, T1, T2) were represented as multiples of the respective T1 for each mouse. Tumor sizes in the NCTD-treated mice were significantly reduced at T2 (*P = 4.5 9 10 -3 ), whereas in vehicle-treated mice they continued to grow. The tumor mass from one mouse in each of the two study groups was then dissected out and embedded in paraffin. As shown by Fig. 4 CTD and NCTD treatment impaired the growth of intracerebellum tumors in orthotopic xenograft nude mice. a Representative images of two orthotopic xenograft mice models generated by implanting DAOY-luc cells into the cerebellum. b The bioluminescence imaging levels of vehicle (DMSO) and NCTD-treated (1 mg/ kg/day) mice were acquired at 0 (T0, before treatment), and after 5 (T2) and 10 (T2) days of daily treatment, and were quantified as photons/s (as multiples of the value for T1). Results are means ± SDs from eight mice in the vehicle-treated group and eight mice in NCTDtreated (1 mg/kg/day) group *P \ 0.5 9 10
. c Hematoxylin staining of the cerebellum from a vehicle-treated animal showed tumor cells growing surrounding the external granular layer (indicated by arrowheads) and destroying the cerebellum layer structure (bars 100 lm). d Immunohistochemistry staining of xenograft tumor from a vehicle-treated mouse showed strong b-catenin staining compared with the xenograft tumor from the NCTD-treated mouse. In contrast, TUJ1 and Gabra6 staining levels were high in the xenograft tumor from the NCTD-treated mouse compared with that from the vehicle-treated mouse (bars 100 lm) hematoxylin staining (Fig. 4c) , the DAOY-luc cells injected in the cerebellum destroyed the layer structure of the cerebellum, resulting in engraftment patterns similar to those for the intracerebellum tumors.
b-Catenin staining of the tumor from the NCTD-treated mouse was reduced compared with the vehicle-treated mouse tumor. Several sections were further stained for neuronal markers. Here, we show that the levels of the TUJ1 and Gabra6 markers were enhanced in the NCTDtreated mouse tumor (Fig. 4d) , thus confirming the results obtained in vitro (Fig. 3a, 3b) . Overall, the results presented here demonstrate that NCTD can cross the BBB, reduce b-catenin expression in the cerebellum, and reduce the tumor burden, thus definitely enhancing the neuronal differentiation process in vivo. Altogether, these findings demonstrate a therapeutic benefit in this xenograft proofof-concept animal study
Discussion
Treatment of infants with MB remains highly problematic. Use of high doses of craniospinal radiation therapy and aggressive chemotherapeutic approaches can result in significant brain injury in patients of all ages, especially in very young children. For this reason, most therapeutic approaches have focused on the use of potentially neurotoxic drugs [1] . As brain tumors, MB are a particularly difficult challenge because of the less-accessible anatomic location; if drugs cannot cross the BBB this limits their inclusion in any chemotherapeutic protocol. The incorporation of biological agents that target specific signaling pathways and that can cross the BBB will not only make treatment more effective, but also enable reduction of neurotoxic therapy.
Wnt-activated tumors are an independent molecular subgroup in MB which are characterized by a distinct pattern of genomic aberrations [15] . Cross-talk between the PI3 K/Akt and b-catenin pathways occurs in the primary MB, and this is crucial to sustaining MB pathophysiology. Inhibitors that target the PI3K/Akt signaling pathway can affect b-catenin signaling, thus resulting in cytoplasmatic retention of b-catenin. These observations make the Wnt pathway an attractive target for molecular intervention by inhibition of b-catenin activity in the nucleus [44] [45] [46] .
In this study we investigated the antitumor activity of two PP1/PP2A inhibitors, CTD and NCTD, on MB cell lines in vitro and in vivo. PP1 and PP2A regulate the activation of kinases that control the balance between cell adhesion and detachment. PP2A inhibition leads to anoikis and caspase activation, which does not occur until after the cells have become detached from the substratum [47] . In our cell lines, similar to previous reports with other cancer cell lines, we show that CTD and NCTD lead to cell detachment with significant down-regulation of N-cadherin protein [48] and caspase-3 activation. Furthermore, a variety of increases and decreases in kinase and phosphatase activity are necessary to complete the cell-cycle process. It is thus not surprising that in our CTD and NCTD-treated cells there is marked G2 cellcycle arrest [28, 49, 50] .
PP2A is required for Wnt-mediated b-catenin stabilization downstream of the Wnt ligand [36] . Although previous evidence has shown a correlation between NCTD treatment and Wnt impairment [51] , we show here for the first time that these two compounds can impair endogenous Wnt-b-catenin signaling in MB cell lines by promoting loss of nuclear b-catenin. Furthermore, the ability to impair the direct Wnt target survivin can be regarded as a new interesting aspect for treatment of unfavorable MB tumors, given that high survivin expression is associated with unfavorable patient outcome in MB, as is also seen in other forms of cancer [52] . At the same time, because Wntactivated signals have cross-talk with additional signaling pathways, for example those of Hh [53] , TGF [54] , and Notch [55] , we cannot at present exclude the possibility that CTD and NCTD can affect other pathways also.
By impairing nuclear activated b-catenin, these compounds lead to increased location of the b-catenin/E-cadherin complex on the cell surface [56] through the function of b-catenin in the linking of the adherens junction to the cytoskeleton. As NCTD is much less toxic than CTD in vivo [22, 29-34, 43, 57] and as it has inhibitory effects on the Wnt/bcatenin pathway, it might be a promising drug for treatment of MB. Furthermore, in this study, NCTD can cross the BBB to affect local tumorigenesis in the cerebellum in the MB orthotopic xenograft animal model, thus overcoming this limiting aspect of clinical management of these tumors.
Interestingly, NCTD had an enhanced differentiation effect, both in vivo and in vitro, thus promoting its clinical use. Indeed, the Wnt/b-catenin signaling pathway is important in the regulation of neural development [58] , because activation of b-catenin leads to proliferation of the neural progenitor pool, which results in inhibition of neuronal differentiation [59] . Although we observed a therapeutic benefit in vivo, use of a xenograft proof-of-concept animal model using only one cell line (DAOY-luc) limits, at this time, rapid extrapolation of these results to human oncology.
In conclusion, the ability of NCTD to cross the BBB and to enhance neuronal differentiation in vivo is a new important finding that relates directly to its therapeutic use in treatment of tumors of the central nervous system. These results and the NCTD effects that impair Wnt signaling in these MB cell lines support the future use of NCTD for specific treatment of the Wnt-activated MB subgroup. In the near future, there is a need to evaluate the NCTD toxicity dose and its pharmacokinetics, before applying this knowledge to use of NCTD in clinical studies.
